New drug trial targets Tough-to-Treat HER2 cancers, including brain spread
Disease control
Recruiting now
This is an early-stage study to find a safe and effective dose of a new drug called IAM1363 for people with advanced cancers that have specific changes in a protein called HER2. The trial will enroll about 243 adults whose cancer has worsened after standard treatments, including …
Phase: PHASE1 • Sponsor: Iambic Therapeutics, Inc • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC